Compare Wockhardt with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs FRESENIUS KABI ONCO. - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT FRESENIUS KABI ONCO. WOCKHARDT/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -23.9 22.1 - View Chart
P/BV x 1.3 3.1 40.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
FRESENIUS KABI ONCO.
Mar-13
WOCKHARDT/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,012176 575.0%   
Low Rs53279 677.1%   
Sales per share (Unadj.) Rs355.937.7 944.3%  
Earnings per share (Unadj.) Rs-60.35.1 -1,183.5%  
Cash flow per share (Unadj.) Rs-46.86.7 -695.5%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.842.5 606.0%  
Shares outstanding (eoy) m110.63158.23 69.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.4 64.2%   
Avg P/E ratio x-12.825.0 -51.2%  
P/CF ratio (eoy) x-16.518.9 -87.2%  
Price / Book Value ratio x3.03.0 100.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,37920,135 424.0%   
No. of employees `0006.31.2 542.9%   
Total wages/salary Rs m9,371703 1,332.6%   
Avg. sales/employee Rs Th6,295.05,176.2 121.6%   
Avg. wages/employee Rs Th1,498.3610.4 245.5%   
Avg. net profit/employee Rs Th-1,066.3699.6 -152.4%   
INCOME DATA
Net Sales Rs m39,3695,963 660.2%  
Other income Rs m1,20218 6,679.4%   
Total revenues Rs m40,5715,981 678.3%   
Gross profit Rs m181,430 1.3%  
Depreciation Rs m1,495258 579.8%   
Interest Rs m2,555-26 -9,826.5%   
Profit before tax Rs m-2,8301,216 -232.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582-68 5,259.8%   
Tax Rs m257342 75.1%   
Profit after tax Rs m-6,669806 -827.5%  
Gross profit margin %024.0 0.2%  
Effective tax rate %-9.128.1 -32.3%   
Net profit margin %-16.913.5 -125.3%  
BALANCE SHEET DATA
Current assets Rs m33,7965,102 662.5%   
Current liabilities Rs m26,9172,385 1,128.4%   
Net working cap to sales %17.545.6 38.4%  
Current ratio x1.32.1 58.7%  
Inventory Days Days79150 52.9%  
Debtors Days Days89113 78.8%  
Net fixed assets Rs m39,6645,148 770.5%   
Share capital Rs m553158 349.7%   
"Free" reserves Rs m27,9686,556 426.6%   
Net worth Rs m28,5226,732 423.7%   
Long term debt Rs m21,731952 2,282.2%   
Total assets Rs m81,62010,388 785.7%  
Interest coverage x-0.1-45.8 0.2%   
Debt to equity ratio x0.80.1 538.7%  
Sales to assets ratio x0.50.6 84.0%   
Return on assets %-5.07.5 -67.1%  
Return on equity %-23.412.0 -195.3%  
Return on capital %-7.714.6 -52.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m9,8075,298 185.1%   
Fx outflow Rs m1,7891,772 100.9%   
Net fx Rs m8,0193,525 227.4%   
CASH FLOW
From Operations Rs m6841,274 53.7%  
From Investments Rs m6,302-1,204 -523.4%  
From Financial Activity Rs m-7,695-196 3,923.9%  
Net Cashflow Rs m-664-126 525.7%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 2.3 0.3 766.7%  
FIIs % 7.7 9.6 80.2%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   67,757 42,599 159.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  SUVEN LIFESCIENCES  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare WOCKHARDT With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

SUVEN LIFESCIENCES Surges by 5%; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Sep 16, 2019 | Updated on Sep 16, 2019

SUVEN LIFESCIENCES share price has surged by 5% and its current market price is Rs 294. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index are SUVEN LIFESCIENCES (up 5.2%) and WOCKHARDT (up 7.4%). The top losers are AJANTA PHARMA and PIRAMAL ENTERPRISES (down 0.2%).

WOCKHARDT Surges by 9%; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Sep 16, 2019 | Updated on Sep 16, 2019

WOCKHARDT share price has surged by 9% and its current market price is Rs 344. The BSE HEALTHCARE is up by 0.3%. The top gainers in the BSE HEALTHCARE Index is WOCKHARDT (up 8.7%). The top losers are SUN PHARMA and ERIS LIFESCIENCES LIMITED (down 0.2%).

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Sep 16, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - DISHMAN PHARMA COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS